Organic Active Ingredients TRIZ Cases

A multilayer nano-cell encapsulates botulinum neurotoxin A in alternating oil and water phases for transdermal skin penetration.

Trehalose inhibits protein kinase B to activate the CLEAR gene network, clearing undegraded materials that accumulate in lysosomal storage disorders.

Dual-action opioid receptor modulators mitigate dyskinesia severity through targeted mu-antagonist and kappa-agonist activity.

ISIS 721744 targets prekallikrein RNA to reduce protein activity, resolving persistent edema symptoms in refractory patients.

A pharmaceutical compound modulates host cell factors to inhibit coronavirus replication and reduce viral load.

Tricyclic furan-substituted piperidinedione compounds modulate CRBN protein to reduce teratogenic effects while maintaining anti-tumor activity.

Triglyceride oils improve cannabinoid penetration and stability, addressing insufficient absorption for treating acne.

Crystallizing N-[2-(6-fluoro-1H-indol-3-yl)ethyl]-3-(2,2,3,3-tetrafluoropropoxy)benzylamine hydrochloride into polymorphic form III via controlled organic solvent suspension.

Nitazoxanide induces IFITM gene transcription to inhibit viral replication, addressing high mortality from rapid disease progression.

Administering (5R)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-L-prolinamide to treat small fibre neuropathy.

JMX0207 modifies niclosamide structure to overcome poor bioavailability and improve in vivo efficacy against Zika virus.

Long-chain menaquinones carboxylate protein S, restoring anticoagulant activity to counteract diet-induced thrombosis risk.

Aqueous TNFR:Fc formulation uses polysorbate 20 and sucrose to maintain polypeptide bioactivity in liquid storage.

Encapsulated granulosa and theca cells deliver controlled estrogens, avoiding high serum concentrations that cause heart disease.

Tetrahedral L-DNA nanoparticles protect siRNA from degradation and enable renal targeting, reducing p53 expression in acute kidney injury.

Segmented unit dose prefilled syringe containing dry powder glucocorticoid reduces cataract and glaucoma risks during intravitreal injection.

A triple inhibitor of FAK, SRC, and JAK2 merges with EGFR therapy to overcome acquired resistance mechanisms.

Chemical formation of functionalized calcium phosphate with linker groups creates porous prostheses that eliminate machining costs and mechanical fasteners.

Pyrido[3,2-d]pyrimidine derivatives minimize off-target effects by selectively activating Toll-like receptor 8.

Dynamic estrogen and progestin adjustments suppress breakthrough bleeding while extending coverage to 98 days.

Adjusting post-treatment monitoring periods according to individual patient tolerance reduces resource usage while maintaining safety standards.

Amphiphilic core-shell nanoparticles replace boron cross-linkers in polygalactomannan gels, reducing toxic boron content while preserving mechanical strength.

Aryl myxopyronin derivatives bind the bacterial RNA polymerase switch region, inhibiting gene expression and overcoming rifamycin resistance.

Five-membered-fused-six-membered aza-aromatic compounds enhance ubiquitination of Ras proteins for targeted degradation.

Chemically-stabilized RNA substrates hybridize to poly-A binding protein, impairing nascent translation to treat pain without inducing opioid tolerance.

Synthesized exosome mimicking nanovesicles bypass time-consuming isolation processes while delivering neuroprotective cargo.

Prodrug polymorphs of a venlafaxine derivative enhance oral absorption and stability by reducing hydrophilicity.

Synthetic nanostructures bind cell surface receptors to form vesicle complexes, resolving cargo loading variability and enabling targeted therapeutic delivery.

Combining testosterone with anastrozole in a single implant prevents estradiol conversion, reducing breast cancer risk while treating deficiency.

A cromoglycate cream composition with natural oils and butters enhances hoof growth in ungulates.

Pharmaceutical composition combines opioid analgesics with antihistamines to deliver faster plasma concentrations of the antiemetic agent.

Engineered adipocytes encapsulate anti-cancer prodrugs via pH-sensitive linkers, enabling sustained release within the tumor microenvironment to inhibit growth.

Combining PIM kinase inhibitors with RNA splicing modulators disrupts mRNA splicing to inhibit cancer cell proliferation.

Incorporating tolterodine acetate into methacrylate copolymer adhesive layers increases adhesion force and extends skin attachment duration.

Enhancing plasmin activity via inhibitor downregulation prevents dystrophic calcification while preserving bone integrity and regeneration.

Hydroxypropyl methyl cellulose combined with solid lipid nanoparticles resolves the trade-off between adhesion strength and penetration depth.

N-acetyl-cysteine and gluconic acid solution scavenges reactive oxygen species to reduce oxidative stress.

Novel compounds modulate PPARγ and EGF receptors to inhibit cellular proliferation and induce apoptosis in tumor cells.

Adeno-associated virus vectors deliver CRISPR complexes to the corneal endothelium, resolving off-target effects in Fuchs dystrophy treatment.

Bifunctional compounds recruit IRAK-4 to E3 ligases for targeted ubiquitination and degradation.

Aromatic-cationic peptides reduce MMP-9 expression and increase TIMP-1 levels, limiting left ventricular remodeling after myocardial infarction.

Hydroquinone geldanamycin derivatives resolve solubility and toxicity trade-offs to enable effective cancer therapy.

Formula I compound treats pulmonary hypertension by targeting lung inflammation and vascular cell proliferation, replacing unstable prostacyclin analogs.

Formula II piperazine compounds achieve selective cytotoxicity, sparing normal cells while eradicating tumors.

Chemical modifications to nucleosides within polynucleotide sequences reduce immune activation while maintaining high therapeutic effectiveness.